ライフサイエンスコーパス: IQR

1 ions score vs 2.1 (95% CI, 2.0-2.3) and 2.0 (IQR, 1.5-3.0) for the moderate strategy group.

2 rehensive complication index (CCI) was 26.0 (IQR, 8.7-36.2).

3 R 6.4-13.4]) in the PENFS group: median 8.0 (IQR 7.0-9.0) at baseline to 6.0 (5.0-8.0) at follow-up v

4 5-HIAA concentrations (median difference 0, IQR 0-5; p=0.20).

5 le range (IQR), 682-862) to 315 per 100,000 (IQR, 260-370), while postnatal vaccination produced a mi

6 ction, with an incidence of 728 per 100,000 (IQR, 628-789).

7 onths (IQR, 1,712-2,076) to 791 per 100,000 (IQR, 683-915).

8 le range [IQR], 0.2-2.8) compared with 0.01 (IQR, 0.01-0.2) among children who saw the movie not cont

9 re and 65.0% (0.20 [IQR, 0.05-0.34] to 0.07 [IQR, 0.01-0.23]) for pediatric care.

10 and 317 Travel patients who traveled 107.1 (IQR: 65-247) miles to centers treating 31.9 (IQR: 30.9-3

11 386) bacteria/microL sputum, which was 5.1% (IQR, 2.4%-11%) the concentration of acid-fast microscopy

12 erquartile range (IQR), 0.78-0.89] vs. 1.10 [IQR, 1.02-1.24]; P = 0.001).

13 The median TIL value was 10% (IQR 5-30).

14 given at the maximum tolerated dose was 11 (IQR 4-19).

15 22-132); 16 (27%) died after a median of 12 (IQR, 0-24) days.

16 it carotid lesions (median difference: 0.12; IQR: 0.0 to 0.23; p = 0.008) and high-risk from lower-ri

17 (interquartile range [IQR], 23-76) SAVR, 13 (IQR, 6-22) MV replacement, and 9 (IQR, 4-19) MV repair p

18 rs, and mean peritoneal cancer index was 13 (IQR, 7-18).

19 emic attack/stroke (median difference: 0.13; IQR: 0.07 to 0.32; p = 0.003).

20 (IQR, 4-5) cm H2O, and a backup rate of 14 (IQR, 14-16) breaths/minute.

21 0]; n = 100), and LDV/SOF without TDF (0.15 [IQR, 0.00-0.30]; n = 423).

22 8-0.30]; n = 372), LDV/SOF and TDF/PI (0.17 [IQR, 0.04-0.30]; n = 100), and LDV/SOF without TDF (0.15

23 s in the past 5 years was greater (median 2 [IQR 1-4] for black Caribbean and 2 [1-5] for black Afric

24 ficant differences in MF (median ECV, 28.2%; IQR, 26.2%-30.7% vs 28.3%; IQR, 25.5%-31.4%; P = .60) or

25 le group, 8%; IQR, 2 to 17% vs. placebo -2%; IQR, -7 to +1%; P = 0.042).

26 nd a median body mass index of 27.8 kg/m(2) (IQR, 26.0-33.1 kg/m(2)).

27 0.53-0.76]) for adult care and 65.0% (0.20 [IQR, 0.05-0.34] to 0.07 [IQR, 0.01-0.23]) for pediatric

28 Ragh incurred delivery costs (mean US$66.20, IQR $61.30 in Kabul and $9.89, $11.87 in Ragh).

29 cid-fast microscopy-positive bacteria (2069 [IQR, 1358-3734] bacteria/muL).

30 0.5-27.5) following FUS thalamotomy and 22% (IQR, -11% to 29%) from a baseline of 23 points (IQR, 14.

31 inspiratory positive airway pressure of 24 (IQR, 22-26) cm H2O, an expiratory positive airway pressu

32 ns was low and increased modestly from 0.25 (IQR, 0.14-0.39) to 0.32 (IQR, 0.19-0.46).

33 es ranged from 2 to 77; median score was 25 (IQR 16-35).

34 Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received fluclox

35 at did not meet benefit thresholds (US$2981 [IQR 320-9059] vs $8621 [1174-13 930]; p=0.018).

36 group were 11.6% (IQR: 6.9-19.9%) and 20.3% (IQR: 14.2-25.7%), respectively, (P < 0.001) and, in the

37 edian ECV, 28.2%; IQR, 26.2%-30.7% vs 28.3%; IQR, 25.5%-31.4%; P = .60) or prognosis (log-rank 0.8; P

38 ates had a median waitlist MELD score of 31 (IQR 27-34) when the liver was exported.

39 modestly from 0.25 (IQR, 0.14-0.39) to 0.32 (IQR, 0.19-0.46).

40 decreased from 39% (IQR, 33% to 44%) to 34% (IQR, 24% to 42%) (P < .001) (rate -3.3% per 5 years; IQR

41 e" had higher median price per ounce ($1.38; IQR, $0.86-$1.63) than products without the claim ($0.59

42 o 41) (P < .001), RV-FAC decreased from 39% (IQR, 33% to 44%) to 34% (IQR, 24% to 42%) (P < .001) (ra

43 aller median 24-hour infarct core of 17.3ml (IQR, 11.3-32.8) versus 24.3ml (IQR, 16.7-42.2; p = 0.011

44 re of 17.3ml (IQR, 11.3-32.8) versus 24.3ml (IQR, 16.7-42.2; p = 0.011) in alteplase-treated controls

45 6.7-147.7), 40.6 (IQR, 15.2-59.6), and 31.4 (IQR, 17.3-86.3) months for patients with cancers of the

46 nterquartile range [IQR], 22.0-111.0), 70.4 (IQR, 26.7-147.7), 40.6 (IQR, 15.2-59.6), and 31.4 (IQR,

47 tile range [IQR]: 62.5 to 92.6) versus 82.4 (IQR: 67.6 to 93.5; p = 0.025) and were more likely to re

48 an expiratory positive airway pressure of 4 (IQR, 4-5) cm H2O, and a backup rate of 14 (IQR, 14-16) b

49 e {IQR}, 0.0-0.7%] of baseline; males: 3.4% [IQR, 0.4%-32.9%] of baseline; P < .001).

50 Median CD4 count was 430 (IQR, 190-620) cells/microL.

51 d follow-up in the PENFS group: median 24.5 (IQR 16.8-33.3) at baseline to 12 (3.6-22.5) at follow-up

52 onths after ART initiation, lasting for 7.5 (IQR, 4.1-20.3) months.

53 roup, were 18.8% (IQR: 8.3-37.5%) and 25.5% (IQR: 15.1-37.8%), respectively (P = 0.124).

54 follow-up visits over 8.6 years (median 6.5, IQR 4.1-7.2).

55 .27) than products without the claim ($0.59; IQR, $0.34-$0.92).

56 .63) than products without the claim ($0.59; IQR, $0.35-$0.91).

57 -4 miles] miles to centers that treated 2.6 (IQR: 1.9-3.3) esophageal cancers per year, and 317 Trave

58 mber of circulating neoplastic cells of 4.6 (IQR 2-12) cells per muL.

59 , 22.0-111.0), 70.4 (IQR, 26.7-147.7), 40.6 (IQR, 15.2-59.6), and 31.4 (IQR, 17.3-86.3) months for pa

60 brief psychosocial intervention group (n=6 [IQR 4-11]), CBT group (n=9 [5-14]), and short-term psych

61 A and from FeSO4 in the Fe group were 11.6% (IQR: 6.9-19.9%) and 20.3% (IQR: 14.2-25.7%), respectivel

62 cts with 1 or more allergens (median, $0.60; IQR, $0.35-$1.06).

63 edicted, median peak oxygen consumption 62% (IQR, 45-77%) of predicted, and median minute ventilation

64 edication median tremor scores improved 62% (IQR, 22%-79%) from a baseline of 17 points (IQR, 10.5-27

65 d 10.8% (from 0.74 [IQR, 0.65-0.81] to 0.66 [IQR, 0.53-0.76]) for adult care and 65.0% (0.20 [IQR, 0.

66 n 1.8 (95% CI, 1.7 to 2.0) and a median 1.7 (IQR, 1.0-2.0) pulmonary complications score vs 2.1 (95%

67 eaths (4.2%) during a median follow-up of 7 (IQR, 4.1-9.6) years.

68 ic ancestry accounted for a median of 75.7% (IQR 45.8% to 92%) of the variance in methylation associa

69 sputum eosinophil group both before (65.7% [IQR 51.8-81.3] vs 75.7% [59.3-90.2], p<0.0001) and after

70 eased 7.42% in the control group, from $712 (IQR, $202-$1602) (16441 cases) in 2014 to $765 (IQR, $23

71 ithout transfer, decreased 10.8% (from 0.74 [IQR, 0.65-0.81] to 0.66 [IQR, 0.53-0.76]) for adult care

72 -11.38, -5.25 D vs no glaucoma median -2.75; IQR -6.38, -0.75 D; P = .005).

73 , $202-$1602) (16441 cases) in 2014 to $765 (IQR, $233-$1719) (17227 cases) in 2015.

74 with the first interruption occurring 12.8 (IQR, 4.0-36.1) months after ART initiation, lasting for

75 0.001) and, in the Fe+GOS group, were 18.8% (IQR: 8.3-37.5%) and 25.5% (IQR: 15.1-37.8%), respectivel

76 edian percent change: anastrozole group, 8%; IQR, 2 to 17% vs. placebo -2%; IQR, -7 to +1%; P = 0.042

77 itudinal visits over 12.8 years (median 2.8, IQR 1.6-4.6).

78 st CPET, the median peak heart rate was 80% (IQR, 70-88%) of predicted, median peak oxygen consumptio

79 any ingredients in the NACDG (median, $0.83; IQR, $0.47-$1.69) were not statistically more expensive

80 IQR: 65-247) miles to centers treating 31.9 (IQR: 30.9-38.5) cases.

81 lation/carbon dioxide production slope 34.9 (IQR, 27.9-39.4).

82 SAVR, 13 (IQR, 6-22) MV replacement, and 9 (IQR, 4-19) MV repair procedures.

83 rtile range [IQR], 1-1) and again at day 92 (IQR, 89-96).

84 in men [OR=0.69 (95% CI: 0.33); 1.44 for an IQR increase (0.75 ng/mL) in serum PBB-153].

85 ecline of 30% or more was associated with an IQR increase in concentrations of PM10 (1.08, 1.07-1.09)

86 DNA/ml collected a median of 5 months apart (IQR: 2-11 months) were included.

87 41.5-62.2 for chemotherapy plus bevacizumab; IQR 40.8-59.3 for chemotherapy), at which point 415 pati

88 quartile range [IQR] 20-69) in 2011 to 22 d (IQR 2-43) in 2013 (p < 0.001).

89 years visit of the treated eyes was -2.25 D (IQR -5.13, +0.88 D) and of the fellow eyes +1.50 D (IQR

90 13, +0.88 D) and of the fellow eyes +1.50 D (IQR +0.88, +2.25).

91 ter anisometropia (glaucoma, median -8.25 D; IQR -11.38, -5.25 D vs no glaucoma median -2.75; IQR -6.

92 ad fewer median ventilator-free days (1 day [IQR 0 to 17] in the KGF group vs 20 days [13-22] in the

93 2%) were eventually transplanted in 11 days (IQR 3-38 days) using a local (50%), regional (50%) or na

94 id specimens; median follow up was 197 days (IQR 187-209 days) after enrolment, which corresponded to

95 Median duration of treatment was 291 days (IQR 239-354).

96 d were followed up for a median of 335 days (IQR 0-364).

97 e median delay after discharge was 350 days (IQR 223-491).

98 e range [IQR], 33.25-83.0 days) to 0.5 days (IQR, 0.172-0.94 days) and median time to treatment from

99 days) in the prednisolone group and 5 days (IQR, 3-10 days) in the placebo group (adjusted hazard ra

100 e 62-92), and median follow-up was 953 days (IQR 721-1040).

101 of 418) of vaccinees (median onset 9.0 days [IQR 2-12]; median duration 7.0 days [4-9]) versus 3.2% (

102 ventilation in survivors to day 90 (16 days [IQR 13-30] in the KGF group vs 11 days [8-16] in the pla

103 tween women assigned to sildenafil (17 days [IQR 7-24]) and women assigned to placebo (18 days [8-28]

104 was similar for both groups (median 4 days [IQR 3-8] vs 4 [3-8] days, p=0.54).

105 le range (IQR): 44.3-47.8 dBA] and 42.3 dBA (IQR: 40.4-45.5 dBA), respectively.

106 he lower-target group (109 mg per deciliter [IQR, 102 to 118]; 6.1 mmol per liter [IQR, 5.7 to 6.6])

107 e higher-target group (123 mg per deciliter [IQR, 108 to 142]; 6.8 mmol per liter [IQR, 6.0 to 7.9];

108 Baseline median haemoglobin of 10.3 g/dL (IQR 9.3-11.7) increased to 11.4 g/dL (10.9-12.4) after 4

109 The median birthweight was 3,300 g (IQR 2,980-3,615).

110 14, was 49.6 months in each treatment group (IQR 41.5-62.2 for chemotherapy plus bevacizumab; IQR 40.

111 order displacement velocity was +1 mum/hour (IQR, -21 to +49 mum/hour) during posturing and -149 mum/

112 um/hour) during posturing and -149 mum/hour (IQR, -406 to +1 mum/hour) during interruptions, a statis

113 Median time to fixation was 15 hours (IQR 7-24 hours) and delayed fixation was performed in 26

114 rrupting ART had a median of 1 interruption (IQR, 1.0-3.0), with the first interruption occurring 12.

115 median retained weight of women was 0.90 kg (IQR: -1.40, 3.25) at 18 mo postpartum.

116 prophylactic dose of rFIXFc was 58.6 IU/kg (IQR 52.3-64.8) per week.

117 he placebo group (at 5 weeks: median 3.7 kg [IQR 2.8 to 4.8] vs 0.6 kg [-0.3 to 1.4], p<0.0001; at 16

118 HVA concentrations by a median of 25 nmol/L (IQR 11-48; p=0.012); however, there was no significant c

119 liter [IQR, 102 to 118]; 6.1 mmol per liter [IQR, 5.7 to 6.6]) than in the higher-target group (123 m

120 liter [IQR, 108 to 142]; 6.8 mmol per liter [IQR, 6.0 to 7.9]; P<0.001).

121 arct size (6% LV; IQR: 2% to 18% vs. 13% LV; IQR: 7% to 23%; p = 0.006; and p for interaction = 0.005

122 nting reduced the final infarct size (6% LV; IQR: 2% to 18% vs. 13% LV; IQR: 7% to 23%; p = 0.006; an

123 Median 6MWT improvement was 25 m (IQR, 19-47 m).

124 led vs. non-encephalopathic controls (median IQR 3[2-9] vs.36 [33-39]; p < 0.01), and was significant

125 lative to those with normal outcomes (median IQR 2[1-3] vs 28[19-26], p = 0.04).

126 Median (IQR) ICU and hospital stay was 0 (0-2) and 12 (9-18) day

127 vivors, 127 (55.4%) were male with a median (IQR) age of 43 (8-144) months.

128 mean +/- SD age: 53 +/- 13 y) with a median (IQR) follow-up of 5.3 y (4.8-6.1 y) and 357 healthy cont

129 During a median (IQR) of 4.4 (6.2) years of follow-up, the alcohol-relate

130 = 30) or a higher-protein group at a median (IQR) postnatal age of 7 (6-8) days.

131 The mean (SD) CAP and median (IQR) LS values at baseline were 249.7 +/- 58.1 dB/m and

132 l subjects was 27.7 +/- 18.9 nmol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] and showed signif

133 ding volume provided as breast milk: median (IQR) proportion of breast milk, 92% (79%-98%) in the low

134 better lung function (FEV1 % pred) [median (IQR): 71.5 (59.0-88.75) vs 69.0 (59.0-77.6) vs 68.0 (60.

135 The median (IQR) age at the second AGV was 68.0 (53.5-77.9) years.

136 of 19 patients [aged 65.8 +/- 7.3 y; median (IQR), 10 (5-9) y of T2D duration; glycated hemoglobin 7.

137 ion rate ranging from 0.73% to 6.0% (median [IQR], 2.5% [1.5%-3.4%]).

138 ; P < .001), higher body mass index (median [IQR], 32.4 [28.1-38.3]; P < .001), less physical activit

139 d few of those residents were women (median [IQR], 12 [5-17]).

140 r commonly used normalization global, median-IQR, quantile, and cyclic loess normalization in simulat

141 pared with an optometrist (median, 46 miles; IQR, 13-125 miles; P = 0.93) or in driving time to an op

142 min) in the oral iron group and 1167 mL/min (IQR, 887-1449 mL/min) in the placebo group.

143 mptying of solids at 5 weeks (median 70 min [IQR 32 to 151] vs 4 min [-21 to 18]; p<0.0001) and 16 we

144 85 minutes), and with GA, it was 35 minutes (IQR, 20-74 minutes) (P = .098).

145 Fluoroscopy time with CS was 49 minutes (IQR, 25-85 minutes), and with GA, it was 35 minutes (IQR

146 e to an ophthalmologist (median, 47 minutes; IQR, 19-110 minutes) compared with an optometrist (media

147 red with an optometrist (median, 50 minutes; IQR, 17-117 minutes; P = 0.76).

148 range [IQR], 29-100 mL) compared with 70 mL (IQR, 33-145 mL) in the control group (P = .19), the abso

149 wer in the liraglutide group (median 750 mL [IQR 651 to 908]) compared with the placebo group (1126 m

150 ients with non-CMV pneumonia, 0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with IPS, and 1.63

151 0 log10 IU/mL) than controls (0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with non-CMV pneumo

152 for patients with IPS, and 1.63 log10 IU/mL [IQR, 0-2.5 log10 IU/mL] for patients who were asymptomat

153 K9 compared with those without (1,500 pg/ml [IQR: 1,000 to 2,300 pg/ml] vs. 1,200 pg/ml [IQR: 827 to

154 [IQR: 1,000 to 2,300 pg/ml] vs. 1,200 pg/ml [IQR: 827 to 1,807 pg/ml], respectively; p < 0.001).

155 ents with either brain or spinal (43.4pg/ml, IQR = 25.2-65.3) or both brain and spinal gadolinium-enh

156 nal gadolinium-enhancing lesions (62.5pg/ml, IQR = 42.7-71.4) had higher sNfL than those without (29.

157 d higher sNfL than those without (29.6pg/ml, IQR = 20.9-41.8; beta = 1.461, p = 0.005 and beta = 1.90

158 to the tauopathy group (median = 12.5pg/ml; IQR = 10.7, 15.0; n = 23; Z = 2.6; p < 0.01).

159 4 ng/mL) than atypical bacteria (0.20 ng/mL; IQR, <0.05-0.87 ng/mL; P = .05), and typical bacteria (2

160 ; P = .05), and typical bacteria (2.5 ng/mL; IQR, 0.29-12.2 ng/mL; P < .01).

161 P < 0.001; and for IL6: median, 1.91 pg/mL; IQR, 1.21-3.02 pg/mL vs median, 2.81 pg/mL; IQR, 1.65-4.

162 IQR], 1.43-2.67 pg/mL vs median, 2.25 pg/mL; IQR, 1.63-3.08 pg/mL, P < 0.001; and for IL6: median, 1.

163 IQR, 1.21-3.02 pg/mL vs median, 2.81 pg/mL; IQR, 1.65-4.97 pg/mL, P < 0.001).

164 terquartile range [IQR], 31 to 39) to 37 mm (IQR, 33 to 41) (P < .001), RV-FAC decreased from 39% (IQ

165 Follow-up was at a median of 12.0 months (IQR 11.8-12.2).

166 Median follow-up was 28.0 months (IQR 14.6-36.6).

167 At a median follow-up of 12.0 months (IQR 8.6-18.0), 23 (31.1%, 95% CI 20.8-42.9) of 74 patien

168 Median follow-up was 11.1 months (IQR 4.8-20.4).

169 Median follow-up was 11.1 months (IQR 5.1-18.0).

170 nalysis, the median follow-up was 14 months (IQR 8-18) for all 91 patients, 19 months (9-27) for the

171 Median follow-up was 23.2 months (IQR 14.8-28.7).

172 ents last known to be alive was 35.2 months (IQR 22.9-39.9).

173 ,000 subsequent children under age 2 months (IQR, 1,712-2,076) to 791 per 100,000 (IQR, 683-915).

174 Median follow-up was 24 months (IQR 24-25).

175 At a median follow-up of 25 months (IQR 12-56), 556 lenalidomide courses had been delivered,

176 During a median follow-up of 27 months (IQR: 6 to 62 months), 50% of group A patients but none o

177 Median follow-up was 43.3 months (IQR 31.6-58.4).

178 dian of 2 sex partners in the last 3 months (IQR = 1-3).

179 Median follow-up was 30 months (IQR 26-37).

180 With a median follow-up of 37 months (IQR 30-44), the estimated 2 year event-free survival was

181 Median follow-up was 10.4 months (IQR 6.5-14.1) in the ipatasertib group and 10.2 months (

182 3%) developed LPI after median of 43 months (IQR, 25-63).

183 At a median follow-up of 45 months (IQR 35-58), median overall survival was 30 months (95% C

184 w-up for surviving patients was 32.5 months (IQR 29.8-34.1).

185 016) after a median follow-up of 8.5 months (IQR 5.5-14.0), 44 (58%; 95% CI 46-69) of 76 patients in

186 Median follow-up was 11.6 months (IQR 5.8-18.2) for the primary analysis.

187 At a median follow-up of 85.6 months (IQR 80.6-95.9) no significant difference was seen in the

188 After a median follow-up of 60 months (IQR 53-72), disease-free survival was 85.8% (95% CI 84.2

189 ia vera, with median durations of 66 months (IQR 35-83) and 53 months (24-70), respectively.

190 Median follow-up was 1.7 months (IQR 1.4-4.1).

191 eatment for the 204 patients was 5.7 months (IQR 2.8-10.1).

192 Median follow-up was 7.7 months (IQR 3.6-12.0) for patients in the rilotumumab group and

193 with median follow-up times of 12.8 months (IQR 9.3-15.5) in the ipilimumab every-12-weeks cohort an

194 with selumetinib + docetaxel and 2.8 months (IQR, 1.4-5.5) with placebo + docetaxel (difference, 1.1

195 were followed up for a median of 83 months (IQR 69-94 months).

196 2015, at a median follow-up of 24.9 months (IQR 24.3 to not attainable), 131 patients had died: 70 (

197 Median follow-up was 15.9 months (IQR 7.8-22.0) at the data cutoff (April 28, 2017).

198 er a median observation time of 17.9 months (IQR 9.1-28.1), the hazard ratio for progression-free sur

199 At the last evaluation (median 50.0 months [IQR 27.0-78.4]), 189 (51%) of 368 patients developed cli

200 ysis (median follow-up duration 24.1 months [IQR 19.5-26.1]).

201 d patients without TAMs (60.5 cells per muL [IQR 21.0-128.0] in patients with TAMS vs 95.0 cells per

202 atients (median CD4 count 165 cells per muL [IQR 75-271]), 163 (14%) had culture-confirmed tuberculos

203 7% more wrinkle on upper lip per increase of IQR, P-value 0.0218).

204 n forehead (12.5% more spots per increase of IQR, P-value 0.0371), and wrinkle on upper lip (7.7% mor

205 ive HF cost reduction of $7,433 per patient (IQR: $7,000 to $7,884), and was robust in analyses restr

206 (IQR, 22%-79%) from a baseline of 17 points (IQR, 10.5-27.5) following FUS thalamotomy and 22% (IQR,

207 , -11% to 29%) from a baseline of 23 points (IQR, 14.0-27.0) after sham procedures; the between-group

208 res were increased by a median of 62 points (IQR 39-93; p=0.005) and HVA concentrations by a median o

209 ual acuity (BCVA) was 20/30 at presentation (IQR, 0.00-0.50) and remained at 20/30 throughout all fol

210 follow-up of 48 months [interquartile range (IQR) 36].

211 For an interquartile range (IQR) increase in PBB-153 (0.43 ng/mL), the OR (any thyro

212 The median interquartile range (IQR) time from reaction to peak MCT was 1.34 (0.82-2.51)

213 d-paced subjects (0.84 [interquartile range (IQR), 0.78-0.89] vs. 1.10 [IQR, 1.02-1.24]; P = 0.001).

214 ren under age 2 months (interquartile range (IQR), 682-862) to 315 per 100,000 (IQR, 260-370), while

215 ients who traveled 2.7 [interquartile range (IQR): 1.6-4 miles] miles to centers that treated 2.6 (IQ

216 eighted decibels (dBA) [interquartile range (IQR): 44.3-47.8 dBA] and 42.3 dBA (IQR: 40.4-45.5 dBA),

217 follow-up of 5.0 years (interquartile range [IQR] 1.6-7.33 years).

218 nt decreased from 44 d (interquartile range [IQR] 20-69) in 2011 to 22 d (IQR 2-43) in 2013 (p < 0.00

219 vival time was 82 days (interquartile range [IQR] 22-638).

220 edian MELD score of 39 (interquartile range [IQR] 37-40) with 30-day posttransplant survival of 96%.

221 follow-up = 3.1 years, interquartile range [IQR] = 2.0-4.0).

222 median age of 31 years (interquartile range [IQR] = 24-38) and had a median of 2 sex partners in the

223 oup (median = 7.4pg/ml; interquartile range [IQR] = 6.0, 12.3; n = 26) compared to the tauopathy grou

224 (median difference and interquartile range [IQR] before and after treatment: -23 g/mL . min [P = .05

225 Median (interquartile range [IQR]) Acute Physiology and Chronic Health Evaluation IV

226 % women) with a median (interquartile range [IQR]) age of 54 (45-63) years and 2521 deaths (4.2%) dur

227 re male and the median (interquartile range [IQR]) age was 69 (17-156) months.

228 The median (interquartile range [IQR]) Hospital Capability Index, reflecting the likeliho

229 Programs had a median (interquartile range [IQR]) number of 30 (20-48) categorical residents, and fe

230 price per ounce ($0.79; interquartile range [IQR], $0.56-$1.27) than products without the claim ($0.5

231 pathogens (0.09 ng/mL; interquartile range [IQR], <0.05-0.54 ng/mL) than atypical bacteria (0.20 ng/

232 ontaining guns was 2.8 (interquartile range [IQR], 0.2-2.8) compared with 0.01 (IQR, 0.01-0.2) among

233 imaging scan at day 1 (interquartile range [IQR], 1-1) and again at day 92 (IQR, 89-96).

234 surgery was 2.2 months (interquartile range [IQR], 1.2, 3.5 months).

235 ha: median, 1.92 pg/mL; interquartile range [IQR], 1.43-2.67 pg/mL vs median, 2.25 pg/mL; IQR, 1.63-3

236 urvival was 3.9 months (interquartile range [IQR], 1.5-5.9) with selumetinib + docetaxel and 2.8 mont

237 gist (median, 39 miles; interquartile range [IQR], 13-113 miles) compared with an optometrist (median

238 first FS was 21 months (interquartile range [IQR], 14-31 months).

239 loads (3.9 log10 IU/mL; interquartile range [IQR], 2.6-6.0 log10 IU/mL) than controls (0 log10 IU/mL

240 cell layers to surface; interquartile range [IQR], 21.4-28.8) vs patients with ERD (median, 23 cell l

241 count 53 cells/microL (interquartile range [IQR], 22-132); 16 (27%) died after a median of 12 (IQR,

242 rall survival was 61.2 (interquartile range [IQR], 22.0-111.0), 70.4 (IQR, 26.7-147.7), 40.6 (IQR, 15

243 an annual volume of 43 (interquartile range [IQR], 23-76) SAVR, 13 (IQR, 6-22) MV replacement, and 9

244 inogen group was 50 mL (interquartile range [IQR], 29-100 mL) compared with 70 mL (IQR, 33-145 mL) in

245 stmarket modifications (interquartile range [IQR], 3-24.8) across a median 10.0-year iterated life sp

246 gh duration was 5 days (interquartile range [IQR], 3-8 days) in the prednisolone group and 5 days (IQ

247 (median age, 38 years; interquartile range [IQR], 30-46 years) eligible for the breast cancer analys

248 n increased from 35 mm (interquartile range [IQR], 31 to 39) to 37 mm (IQR, 33 to 41) (P < .001), RV-

249 luation from 70.0 days (interquartile range [IQR], 33.25-83.0 days) to 0.5 days (IQR, 0.172-0.94 days

250 pient age was 52 years (interquartile range [IQR], 41-62 years) and 58 years (IQR, 50-64 years), resp

251 dian age of 52.3 years (interquartile range [IQR], 43.7-57.6 years) and a median body mass index of 2

252 ve for a median of 119 (interquartile range [IQR], 47-386) bacteria/microL sputum, which was 5.1% (IQ

253 Mean age was 54 (interquartile range [IQR], 47-64) years, and mean peritoneal cancer index was

254 ian age was 67.8 years (interquartile range [IQR], 62.1-73.8 years).

255 ak Vo2 was 1196 mL/min (interquartile range [IQR], 887-1448 mL/min) in the oral iron group and 1167 m

256 -up time of 10.1 years (interquartile range [IQR], 9.1-11.5) progression of CAD occurred at similar r

257 median age 12.6 years (interquartile range [IQR], 9.9-14.6 years).

258 and after treatment and interquartile range [IQR]: -17 g/mL. min, respectively [P = .0001], for olapa

259 edian difference: 0.69; interquartile range [IQR]: 0.22 to 1.15; p = 0.008) and transient ischemic at

260 a median of 15 h/week (interquartile range [IQR]: 10 to 20 h/week) for a median of 13 years (IQR: 10

261 ty of Life score of 80 (interquartile range [IQR]: 62.5 to 92.6) versus 82.4 (IQR: 67.6 to 93.5; p =

262 DP arm (females: 0.05% [interquartile range {IQR}, 0.0-0.7%] of baseline; males: 3.4% [IQR, 0.4%-32.9

263 e inhibitor (PI) (0.18 [interquartile range {IQR}, 0.08-0.30]; n = 372), LDV/SOF and TDF/PI (0.17 [IQ

264 7 [46%] female; median [interquartile range {IQR}] age, 56 [44-66] years), 250 were "at risk" for HFp

265 cross a median 10.0-year iterated life span (IQR, 4.1-16.7).

266 distal (median, 9.5 cell layers to surface; IQR, 1.5-13.3; P < .0001 vs ERD, BE, and controls) and p

267 with ERD (median, 23 cell layers to surface; IQR, 16-27.5), or patients with BE (median, 21.5 cell la

268 ith BE (median, 21.5 cell layers to surface; IQR, 16.1-27.5).

269 roximal (median, 5.0 cell layers to surface; IQR, 2.5-9.3 vs median 10.4 cell layers to surface; IQR,

270 5-9.3 vs median 10.4 cell layers to surface; IQR, 8.0-16.9; P = .0098 vs controls).

271 urine fluoride of 0.5mg/L (approximately the IQR) predicted 3.15 (95% CI: -5.42, -0.87) and 2.50 (95%

272 IQR 61-74], median previous therapies three [IQR 2-4]).

273 Patients received a median of two (IQR 1-2) previous therapies.

274 or patients on first-line ART and 101 weeks (IQR 51-178) for patients on second-line ART.

275 Median duration of follow-up was 124 weeks (IQR 56-221) for patients on first-line ART and 101 weeks

276 an time to improved response was 12.2 weeks (IQR 7.2-22.5) in the lenalidomide group versus 76.3 week

277 extended period (median follow-up 9.2 weeks [IQR 6.4-13.4]) in the PENFS group: median 8.0 (IQR 7.0-9

278 The median pregnancy duration was 39 wk (IQR 38-40) although there were significant differences b

279 rm on NO2 is larger for small cities (beta x IQR = -0.46 for cities < approximately 300000 people, ve

280 table RTRs with a median follow-up of 5.3 y (IQR: 4.8-6.1 y) and 297 healthy controls, PLP, plasma 3-

281 were followed up for a median of 5.0 years (IQR 3.4-6.0) in both groups.

282 After a median follow-up of 11 years (IQR 10.09-11.53), random assignment to 1 year of trastuz

283 : 10 to 20 h/week) for a median of 13 years (IQR: 10 to 18 years).

284 After a median follow-up of 5.2 years (IQR 2.1-5.3), patients in the neratinib group had signif

285 The median time to death was 4.2 years (IQR, 2.2-7.1 years).

286 first postmarket safety event was 4.2 years (IQR, 2.5-6.0 years), and the proportion of novel therape

287 Median age of women was 26 years (IQR 21-37; range 18-52).

288 Median follow-up was 5.3 years (IQR 3.0-10.0, maximum 23 years).

289 (46%) were men, the median age was 34 years (IQR: 27-44), and 130 (28%) were HIV seropositive.

290 In these patients, median age was 58 years (IQR 51-62), median number of previous lines of therapy w

291 tile range [IQR], 41-62 years) and 58 years (IQR, 50-64 years), respectively.

292 Median treatment duration was 2.6 years (IQR 2.0-3.4; 136 weeks) and median observation time was

293 event during median follow-up of 3.7 years (IQR 2.7-4.8).

294 During a median follow-up of 2.7 years (IQR, 1.5-4.6 years) in the main study group, diabetes wa

295 After a median follow-up of 7.9 years (IQR 5.6-11.1), 210 colorectal cancers were diagnosed.

296 293 patients (median age 55 years [IQR 45.0-65.5]) were included in the longitudinal study,

297 enrolled 261 patients (median age 68 years [IQR 61-74], median previous therapies three [IQR 2-4]).

298 analysis, 5066 women (median age, 38 years; IQR, 31-47 years) eligible for the ovarian cancer analys

299 lysis, and 2213 women (median age, 47 years; IQR, 40-55 years) eligible for the contralateral breast

300 to 42%) (P < .001) (rate -3.3% per 5 years; IQR, -8.9% to 1.2%), indicating large interpatient varia